NIH announced “three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack.”  Total funding for the three awards could reach US$68 million depending on the successful completion of defined project milestones. NIAID Director Anthony S. Fauci, M.D. commented, “These new contracts build on NIAID’s commitment to support the advanced development of products that are important to the public health but often unattractive to investors in private industry, by bridging the funding gap with contracts intended to address specific health needs.” The three studies will focus on a dengue vaccine delivered by a needle-free device, an anthrax vaccine delivered orally, and an anthrax vaccine delivered in conjunction with an adjuvant. Clinical trials of all three vaccine products should begin within three years, FDA noted

http://www.nih.gov/news/health/oct2010/niaid-07.htm